Effects of Ranolazine on Recurrent Cardiovascular Events in Patients With Non–ST-Elevation Acute Coronary Syndromes<SUBTITLE>The MERLIN-TIMI 36 Randomized Trial</SUBTITLE>

Abstract

clinicaltrials.gov Identifier: NCT00099788.

Effect of Ranolazine on Ischemic Myocardium IN Patients With Acute Cardiac Ischemia (RIMINI-Trial): A Randomized Controlled Pilot Trial

“…Six weeks after coronary intervention, the cumulative global strain rate was higher in the ranolazine than in the standard treatment group. This is in line with results from other studies showing a reduction in the risk of recurrent ischemia, worsening of angina and fewer increases in other antianginal therapy in non-STsegment elevation myocardial infarction, [1][2][3] and improved myocardial perfusion in patients with stable CAD on exercise treadmill. 12 Obtained results were not significantly different; however, this study was not powered for statistical significance, but rather a pilot trial to create a follow-up trial with enough statistical power.…”

Efficacy of Ranolazine in Patients With Chronic Angina

“…Among patients with prior angina, the primary end point (cardiovascular death, MI, or recurrent ischemia) was lower in patients treated with ranolazine compared with placebo (25.2% vs. 29.4%, HR: 0.86; 95% CI: 0.75 to 0.97; p ϭ 0.017); however, this effect was driven entirely by the impact of ranolazine on recurrent ischemia. Ranolazine had no effect on the risk of cardiovascular death or MI in the patients with prior angina (HR: 0.97; 95% CI: 0.80 to 1.16, p ϭ 0.71), consistent with the result in the overall cohort (16). In contrast, ranolazine significantly reduced the incidence of each of the major end points with respect to its antianginal efficacy (Fig.…”

Trends in Enrollment, Clinical Characteristics, Treatment, and Outcomes According to Age in Non–ST-Segment–Elevation Acute Coronary Syndromes Clinical Trials

“…However, trends over time, including enrollment by age, were comparable to other NSTE ACS trials conducted during the same period. 20–25 Other recent large, multinational, phase III, NSTE ACS trials had comparable findings to the more recent trials in our series, although fewer patients aged ≥75 years were studied. 26–29 Finally, overall rates of treatment and outcomes were comparable to those observed in practice registries.…”